GlassScriptPhysician profile
Peter C Kurniali
NPI 1922236793
$7,712.04
in general payments reported to CMS, 2019-2025
72 companies · $3,527 in 2025
The $3,527 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $176 · 2022: $268 · 2023: $1,110 · 2024: $1,908 · 2025: $3,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Consulting Fee: $1,650 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.27 |
| Consulting Fee | $1,650.00 |
| Education | $188.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,774.34 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $469.53 | 2019-2025 | Enhertu, Injectafer, Vanflyta |
| Pfizer INC. | $380.23 | 2019-2025 | |
| Janssen Biotech, INC. | $348.45 | 2019-2025 | Darzalex, Talvey, Carvykti |
| Tempus Ai, INC | $334.81 | 2024 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $314.80 | 2019-2025 | Enhertu, Imfinzi |
| Abbvie INC. | $288.92 | 2019-2025 | |
| Eisai INC. | $250.03 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $216.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $194.34 | 2019-2025 | Keytruda, Welireg |
| Aveo Pharmaceuticals, INC. | $164.83 | 2022-2025 | |
| Amgen INC. | $157.73 | 2019-2023 | Lumakras, Kyprolis |
| Sirtex Medical INC | $147.65 | 2019 | |
| Sobi, INC | $143.44 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $119.61 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $115.39 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmaessentia USA Corporation | $110.97 | 2024-2025 | Besremi |
| Tersera Therapeutics LLC | $108.94 | 2019-2025 | Zoladex, Xermelo |
| Glaxosmithkline, LLC. | $101.44 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $96.72 | 2020-2025 | Polivy, Lunsumio, Tecentriq |
| Celgene Corporation | $80.69 | 2019-2024 | Opdualag, Reblozyl |
| Myriad Genetic Laboratories, INC. | $77.75 | 2022-2023 | Mychoice Cdx |
| Taiho Oncology, INC. | $77.33 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $74.96 | 2023-2025 | |
| Gilead Sciences, INC. | $74.33 | 2019-2025 | Trodelvy |
| Progenics Pharmaceuticals, INC. | $66.26 | 2022 | |
| Astellas Pharma US INC | $65.53 | 2019-2023 | Xospata, Padcev |
| Exelixis INC. | $64.17 | 2019-2023 | Cabometyx |
| Karyopharm Therapeutics INC. | $64.14 | 2023-2025 | Xpovio |
| Emd Serono, INC. | $63.76 | 2019-2024 | Bavencio |
| Takeda Pharmaceuticals U.S.A., INC. | $57.74 | 2019-2025 | Fruzaqla, Alunbrig |
| Geron Corporation | $54.94 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $51.37 | 2019-2024 | Zepzelca |
| Genzyme Corporation | $51.29 | 2023-2025 | |
| Edwards Lifesciences Corporation | $50.46 | 2023 | Sapien 3 Ultra Resilia |
| Alexion Pharmaceuticals, INC. | $48.23 | 2019-2025 | Ultomiris |
| Kyowa Kirin, INC. | $46.34 | 2024-2025 | Poteligeo |
| Seagen INC. | $45.26 | 2019-2023 | Adcetris |
| Array Biopharma INC | $43.17 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Beone Medicines USA, INC. | $41.26 | 2025 | Brukinsa |
| Deciphera Pharmaceuticals INC. | $40.87 | 2025 | Romvimza, Qinlock |
| Pharmacosmos Therapeutics INC. | $36.86 | 2024 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $34.52 | 2019-2024 | Somatuline Depot, Onivyde |
| Rigel Pharmaceuticals, INC. | $33.90 | 2023-2024 | Rezlidhia, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $33.28 | 2019-2025 | |
| Adc Therapeutics America, INC. | $32.01 | 2024-2025 | |
| Stemline Therapeutics INC. | $30.51 | 2023-2024 | Orserdu, Elzonris |
| Legend Biotech USA INC. | $29.94 | 2025 | Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.94 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $25.78 | 2023 | Libtayo |
| Sumitomo Pharma America, INC. | $22.72 | 2024 | Orgovyx |
| Blueprint Medicines Corporation | $22.22 | 2023 | Ayvakit |
| Azurity Pharmaceuticals, INC. | $22.02 | 2025 | Danziten |
| Mirati Therapeutics, INC. | $21.55 | 2023 | Krazati |
| Immunogen, INC. | $20.30 | 2023 | Elahere |
| Coherus Oncology, INC. | $19.71 | 2024 | |
| Puma Biotechnology, INC. | $18.70 | 2025 | |
| Foundation Medicine, INC. | $17.91 | 2023 | |
| Genmab U.S., INC. | $17.07 | 2023 | Epkinly |
| Amag Pharmaceuticals, INC. | $16.91 | 2019 | |
| Recordati_rare_diseases_inc. | $15.98 | 2025 | Enjaymo |
| Springworks Therapeutics, INC. | $15.21 | 2025 | Ogsiveo |
| Tesaro, INC. | $14.69 | 2019 | |
| Kite Pharma, INC. | $14.68 | 2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $13.46 | 2023 | Imbruvica |
| Agios Pharmaceuticals, INC. | $13.40 | 2024 | |
| G1 Therapeutics, INC. | $13.13 | 2023 | Cosela |
| Janssen Pharmaceuticals, INC | $12.49 | 2024 | Xarelto |
| Octapharma USA, INC. | $12.48 | 2019 | |
| Shire North American Group INC | $11.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kurniali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.